SecBot SecBot

INCY

INCYTE CORP
Nasdaq· Services-Commercial Physical & Biological Research· Inc. DE· CIK 0000879169 Biotech & Drug Discovery
$120.27 −0.70 (−0.58%)
Nov 16 4:00 PM ET · prev $120.97
Market cap
$24.8B
Large cap
Consensus
Buy
54% Buy or better · 35 analysts
Median target
🔒 Subscribers only
1 year
+15.5%
from $104.17 · Nov 17
30 days
+6.2%
from $113.25
52-week range
$90.30–129.93
−7% from high · low Mar 27
Avg volume 20D
1.77M
shares / day
Short interest
10.65M
≈5.2% of shares · +6.2%
Days to cover
5.6
at average volume
Insider net
−$38.5M
0 buyers · 4 sellers · since Jul 31
New fund stakes
1
Q2 2026 13F · 1 exit
Filing reports
17
analyzed by SecBot
SecBot read BULLISH 8 reports · 90 days
Balance 0 bearish · 2 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 6/8

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $38.5M.

  • InstitutionsBULLISH

    Q2 2026: 46 added (1 new), 29 trimmed or exited. Largest new: Hrt Financial $17.0M.

  • AnalystsBULLISH

    19 of 35 rate it Buy or better.

  • Short sellersSTEADY

    Short interest +6.2% to 10.65M shares. 5.6 days to cover, ≈5.2% of shares.

  • TrendUPTREND

    1% above its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
1
exit
$17.0M
in new stakes
FundMoveSharesValue
HSBC HOLDINGS PLCDOUBLED1,307,743$148.3M
PANAGORA ASSET MANAGEMENT INCTRIM881,889$100.0M
JPMORGAN CHASE & COADD761,690$87.3M
UBS Group AGTRIM767,924$87.1M
JACOBS LEVY EQUITY MANAGEMENT, INCTRIM731,774$83.0M
BANK OF AMERICA CORP /DE/TRIM676,191$76.7M
LOS ANGELES CAPITAL MANAGEMENT LLCTRIM578,986$65.6M
SEI INVESTMENTS COTRIM498,013$56.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

35 analysts
Buy 54% rate it Buy or better
Strong Buy9Buy10Hold16Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Nov 5, 2026Leerink Partners
MAINTAIN
MAINTAINOutperform
Nov 2, 2026Bernstein
MAINTAIN
MAINTAINMarket Perform
Oct 30, 2026Wells Fargo
MAINTAIN
MAINTAINEqual-Weight
Oct 30, 2026RBC Capital
MAINTAIN
MAINTAINSector Perform
Oct 30, 2026Barclays
MAINTAIN
MAINTAINOverweight
Oct 30, 2026Evercore ISI Group
MAINTAIN
MAINTAINIn-Line

Washington

Corporate Lobbying

44 lobbying filings and 5 bills this company lobbies on, with spend, stage and how each bill touches it, are for subscribers.

Subscribe for Full Access

Insider ledger

Form 4
$0
bought · 0 insiders
$38.5M
sold · 4 insiders
DateInsiderTypeValue
Nov 6, 2026
Stein Steven H
CMO & Head of Late-Stage Dev.
Nov 6, 2026
EXERCISE$585.9K
Nov 6, 2026
Stein Steven H
CMO & Head of Late-Stage Dev.
Nov 6, 2026
EXERCISE$1.2M
Nov 6, 2026
Stein Steven H
CMO & Head of Late-Stage Dev.
Nov 6, 2026
EXERCISE$2.2M
Nov 6, 2026
Stein Steven H
CMO & Head of Late-Stage Dev.
Nov 6, 2026
EXERCISE$1.8M
Nov 6, 2026
Stein Steven H
CMO & Head of Late-Stage Dev.
Nov 6, 2026
EXERCISE$99.9K
Nov 6, 2026
Stein Steven H
CMO & Head of Late-Stage Dev.
Nov 6, 2026
EXERCISE$891.5K
Nov 6, 2026
Stein Steven H
CMO & Head of Late-Stage Dev.
Nov 6, 2026
EXERCISE$1.3M
Nov 6, 2026
Stein Steven H
CMO & Head of Late-Stage Dev.
Nov 6, 2026
EXERCISE$1.3M

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Congressional trades
INCY trades disclosed by members of Congress, with disclosure delay.
1 members · 2 buys / 1 sells
DateMemberType AmountDisclosed
Oct 7, 2026 Ro KhannaDHouse Spouse account · Incyte Corp SELL $1K–$15K Nov 5, 2026 +29d
Sep 4, 2026 Ro KhannaDHouse Spouse account · Incyte Corp BUY $1K–$15K Oct 7, 2026 +33d
May 15, 2026 Ro KhannaDHouse Spouse account · Incyte Corp BUY $1K–$15K Jun 9, 2026 +25d

Short side

FINRA· Oct 30, 2026
10,649,327
shares short
+6.2%
vs prior settlement
5.6
days to cover
≈5.2%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 13, 2026 SEC
Heeson Lee, an officer of Incyte, filed a Form 144 notice to sell 10,694 shares of common stock with an approximate…
144 · Impact 2/10
Nov 13, 2026 SEC
Incyte announced it will not proceed with the planned Phase 3 MAESTRA-3 study of its CDK2 inhibitor INCB123667 in…
8-K · Impact 3/10
Nov 13, 2026 Drug approval
EMA: Human medicines European public assessment report (EPAR): Ruxolitinib Krka, ruxolitinib, Status: Opinion
Human medicines European public assessment report (EPAR): Ruxolitinib Krka, ruxolitinib, Status: Opi
Nov 12, 2026 SEC
Dodge & Cox filed an amended Schedule 13G disclosing a 5.0% passive stake in Incyte as of September 30, 2026, with…
SC 13G/A · Impact 2/10
Nov 6, 2026 Insider
Stein Steven H acquired via exercise 8,539 shares
CMO & Head of Late-Stage Dev. @ $68.62 ($585.9K)
Nov 6, 2026 Insider
Stein Steven H acquired via exercise 19,749 shares
CMO & Head of Late-Stage Dev. @ $61.18 ($1.2M)
Nov 6, 2026 Insider
Stein Steven H acquired via exercise 19,091 shares
CMO & Head of Late-Stage Dev. @ $113.64 ($2.2M)
Oct 7, 2026 Congress
Ro Khanna sell
$1,001 - $15,000 · House
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
4 drugs tracked · Drug pipeline →
Recent

SecBot reports

17 filings · 4 bullish · 1 bearish · 1 mixed · 11 neutral
All INCY filing & press-release reports (17)